All filters
Abstracts
Two-drug regimen (2DR) for initial HIV treatment? – Lessons learned from 20 years RESINA cohort
N. Lübke  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019
R. Scutari Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Transmitted drug resistance to integrase based first-line HIV antiretroviral treatment in the MeditRes HIV collaboration
F. García Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Exploring Molecular Characteristics and Evolutionary Dynamics of the HIV-1 Epidemic in Montenegro Through Phylogenetic Analyses
S. Dragas Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union
E. Ozhmegova  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M Study
P. Benn Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Short- and long-term direct medical costs of late and very late HIV presentation
L. Versteegh Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018
A. De Vito  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
Y. Bouba Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
J. van Wyk Reviews in Antiviral Therapy & Infectious Diseases 7, 2020  
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 Study
C. Vavro Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
H. Jullien Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
F. Giammarino Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Detection in HIV proviral DNA of drug resistance mutations in patients with low permanent viral loads
P. Ferrer  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy
F. Lombardi Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Role of analytical treatment interruption on HIV peripheral reservoir diversification
C. Alteri  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Comprehensive assessment of SARS-CoV-2 key genetic elements single or in clusters underlying geographically-dependent genetic evolutionary adaptation and their impact on drugs binding affinity and immune escape
M. Alkhatib  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Case report: poor adherence to dolutegravir is associated with selection of resistance mutations T66I, G118R, E138A and L74I
M. Pauskar Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Integrase Resistance development after long-term suppressive treatment with Abacavir, Lamivudine and Dolutegravir
M. Obermeier  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Difficulty in reaching virological suppression in a long-term treated HIV-1 patient: rather the role of the reservoir than drug resistance?
E. Alidjinou Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of quality of life among patients with hepatitis C in Georgia
T. Abzianidze Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV Seronegativity After Rapid ART: A Case Demonstrating Future Challenges in HIV Confirmation Testing in the Era of iART
K. Yan Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Multicentric Castleman Disease HHV-8 related in a HIV patient
A. Gjataj Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020